Committed to developing novel vaccines against major infectious diseases and public health threats worldwide
Patronus Biotech, a subsidiary of Luye Life Sciences Group, focuses on the development, manufacturing and commercialization of new technology route vaccines and strives to be a pioneer in the industry.
With innovative vaccine core technology and an experienced team of scientists, Patronus has establisheda complete industrial chain from R&D, pilot test to commercialization.
Unique U-VLP (Universal VLP) platform
Breaks through the limitations of traditional VLP technology in pathogen types
Stable and high yield:
Breaks bottlenecks of traditional VLP manufacturing technology
Broad spectrum:
Can be used for rapid development of a wide range of pathogenic vaccines, including emergency products such as COVID vaccine
Stronger efficacy:
Particle presentation improves the immunogenicity of otherwise poorly immunogenic protein antigens, together with steric presentation promotes conserved epitopes recognition thus higher broadly neutralising antibody titers
Pilot workshop
Manufacture workshop
TOP